Format

Send to

Choose Destination
Biomed Res Int. 2017;2017:5496398. doi: 10.1155/2017/5496398. Epub 2017 Jan 17.

Antineoplastic Effects of Honokiol on Melanoma.

Author information

1
Department of Pharmaceutical Sciences, South Dakota State University, Brookings, SD 57007, USA.
2
Department of Pharmaceutical Sciences, South Dakota State University, Brookings, SD 57007, USA; Department of Pharmacology & Therapeutics, Roswell Park Cancer Institute (RPCI), Buffalo, NY 14263, USA.
3
Department of Biology and Microbiology; and Department of Veterinary and Biomedical Sciences, South Dakota State University, Brookings, SD 57007, USA.
4
Department of Pharmaceutical Sciences, South Dakota State University, Brookings, SD 57007, USA; University of Maryland Baltimore Washington Medical Center, Glen Burnie, MD 21061, USA.

Abstract

Honokiol, a plant lignan has been shown to have antineoplastic effects against nonmelanoma skin cancer developments in mice. In this study, antineoplastic effects of honokiol were investigated in malignant melanoma models. In vitro effects of honokiol treatment on SKMEL-2 and UACC-62 melanoma cells were evaluated by measuring the cell viability, proliferation, apoptosis, cell cycle analysis, and expressions of various proteins associated with cell cycle progression and apoptosis. For the in vivo study, male nude mice inoculated with SKMEL-2 or UACC-62 cells received injections of sesame oil or honokiol for two to seven weeks. In vitro honokiol treatment caused significant decrease in cell viability, proliferation, cell cycle arrest, increased apoptosis, and modulation of apoptotic and cell cycle regulatory proteins. Honokiol caused an accumulation of cells in the G2/M phase of the cell cycle in SKMEL-2 and G0/G1 phase in UACC-62 cells. An elevated level of caspases and PARP were observed in both cell lines treated with honokiol. A decrease in the expression of various cell cycle regulatory proteins was also observed in honokiol treated cells. Honokiol caused a significant reduction of tumor growth in SKMEL-2 and UACC-62 melanoma xenografts. These findings suggest that honokiol is a good candidate for further studies as a possible treatment for malignant melanoma.

PMID:
28194418
PMCID:
PMC5282456
DOI:
10.1155/2017/5496398
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center